NeuroOne Medical Technologies aims to secure ISO 13485 certification and begin drug delivery availability in the second half of fiscal 2026.
NeuroOne Medical Technologies Corporation outlined plans to achieve ISO 13485 certification in the latter part of 2026. The company also targets launching its drug delivery system in the second half of fiscal 2026.
The certification, a global standard for medical device quality management, is critical for regulatory compliance and market access. NeuroOne’s drug delivery system is expected to expand its product portfolio in neurological applications.
No immediate market reaction was disclosed during the earnings call insights.